Abbvie Inc. vs argenx SE
ABBV vs ARGX — side-by-side comparison from reported financials. ABBV leads 5, ARGX leads 6 of 11 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
argenx SE
ARGX · Healthcare
$825.03+0.78%Strong
| Metric | ABBV | ARGX |
|---|---|---|
| Price | $276.43 | $825.03 |
| Market cap | $488B | $51.9B |
| Revenue (TTM) | $64.4B | $4.24B |
| Revenue growth | +1.8% | +116.2% |
| Net margin | 9.8% | 30.5% |
| Free cash flow | $18.2B | $970M |
| Net cash (debt) | ($56.2B) | $5.14B |
| 1-year price return | +19.8% | +2.5% |
| P/E | 77.4 | 20.1 |
| P/E vs own history (cheap-side %) | 23% | 92% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 22% |
| Altman Z-score | 2.33 | 21.86 |
| CV checks passed | 9 of 11 | 8 of 11 |
| Employees | 57,000 | 1,863 |
Full résumé-style profiles: ABBV CV · ARGX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.